Wstęp
Ta strona zawiera kompleksową analizę znanej historii wykorzystywania informacji poufnych w firmie Henderson Lori M.. Insiderzy to członkowie kadry kierowniczej, dyrektorzy lub znaczący inwestorzy w spółce. Dokonywanie transakcji w ich firmach w oparciu o określone, niepubliczne informacje jest nielegalne. Nie oznacza to, że dokonywanie jakichkolwiek transakcji we własnych firmach jest nielegalne. Muszą jednak zgłaszać wszystkie transakcje do SEC za pośrednictwem formularza 4. Pomimo tych ograniczeń badania akademickie sugerują, że insiderzy – ogólnie rzecz biorąc – mają tendencję do osiągania lepszych wyników na rynku w swoich własnych firmach.
Średnia rentowność handlu
Średnia rentowność handlu to średni zwrot ze wszystkich zakupów na otwartym rynku dokonanych przez osobę mającą dostęp do informacji poufnych w ciągu ostatnich trzech lat. Aby to obliczyć, badamy każdy nieplanowany zakup na otwartym rynku dokonany przez insidera, z wyłączeniem wszystkich transakcji oznaczonych jako część planu handlowego 10b5-1. Następnie obliczamy średnią wydajność tych transakcji w ciągu 3, 6 i 12 miesięcy, uśredniając każdy z tych okresów, aby wygenerować ostateczny wskaźnik wydajności dla każdej transakcji. Na koniec uśredniamy wszystkie wskaźniki wydajności, aby obliczyć wskaźnik wydajności dla insidera. Na tej liście znajdują się wyłącznie insiderzy, którzy dokonali co najmniej trzech transakcji w ciągu ostatnich dwóch lat.
Jeśli rentowność handlu insiderów jest oznaczona notką„nie dotyczy”, oznacza to, że insider albo nie dokonał żadnych zakupów na otwartym rynku w ciągu ostatnich trzech lat, albo transakcje, których dokonał, są zbyt nowe, aby obliczyć wiarygodny wskaźnik wydajności.
Częstotliwość aktualizacji: codziennie
Spółki posiadające zgłoszone stanowiska osób mających dostęp do poufnych informacji
Z dokumentów SEC wynika, że Henderson Lori M. zgłosił udziały lub transakcje w następujących spółkach:
| Papier wartościowy | Nazwa | Najnowsze raporty dotyczące udziałów |
|---|---|---|
| US:MRNA / Moderna, Inc. | General Counsel and Secretary | 328 352 |
| US:AMRI / Albany Molecular Research, Inc. | SVP, Secretary & Gen Counsel | 0 |
Jak interpretować wykresy
Poniższe wykresy przedstawiają notowania akcji papierów wartościowych po każdej niezaplanowanej transakcji na otwartym rynku dokonanej przez Henderson Lori M.. Nieplanowane transakcje to transakcje, które nie zostały dokonane w ramach planu handlowego 10b5-1. Notowania akcji przedstawiono na wykresie jako skumulowaną procentową zmianę ceny akcji. Na przykład, jeśli 1 stycznia 2019 r. dokonano transakcji poufnej, wykres pokaże dzienną procentową zmianę papieru wartościowego do dnia dzisiejszego. Jeżeli cena akcji wzrosłaby w tym czasie z 10 do 15 dolarów, skumulowana procentowa zmiana ceny akcji wyniosłaby 50%. Zmiana ceny z 10$ na 20$ będzie wynosić 100%, a zmiana ceny z 10$ na 5$ będzie wynosić -50%.
Ostatecznie staramy się określić, jak blisko transakcje insiderów korelują z nadmiernymi zwrotami (dodatnimi lub ujemnymi) z ceny akcji, aby sprawdzić, czy insider dostosowuje swoje transakcje w taki sposób, aby czerpać korzyści z informacji poufnych. Rozważmy sytuację, w której zrobił to ktoś z wewnątrz. W tej sytuacji oczekiwalibyśmy albo (a) dodatnich zwrotów po zakupach, albo (b) ujemnych zwrotów po sprzedaży. W przypadku (a) wykres ZAKUPU pokazywałby serię krzywych nachylonych w górę, wskazujących dodatnie zwroty po każdej transakcji zakupu. W przypadku (b) wykres SPRZEDAŻ pokazywałby serię krzywych o nachyleniu w dół, wskazujących ujemne zwroty po każdej transakcji sprzedaży.
Samo to jednak nie wystarczy, aby wyciągnąć wnioski. Gdyby np. cena akcji spółki przez wiele lat rosła niecyklicznie, to spodziewalibyśmy się, że wszystkie wykresy po zakupie będą wykazywały tendencję wzrostową. Podobnie niecykliczne spadki na przestrzeni wielu lat spowodowałyby spadek linii na wykresie po transakcjach. Żaden z tych wykresów nie sugeruje wykorzystywania informacji poufnych.
Najsilniejszym wskaźnikiem byłaby sytuacja, gdy cena akcji miała charakter wyjątkowo cykliczny, a na wykresie KUPNO występowały zarówno pozytywne sygnały na wykresie KUPNA, jak i negatywne na wykresie SPRZEDAŻY. Sytuacja ta wysoce sugerowałaby osobę mającą dostęp do informacji poufnych, która wykorzystywała transakcje w celu uzyskania korzyści finansowej.
Historia handlu insiderów
Ta tabela przedstawia pełną listę transakcji insiderów dokonanych przez firmę Henderson Lori M. ujawnioną Komisji Papierów Wartościowych (SEC).
| Data pliku | Data trans | Formularz | Ticker | Bezpieczeństwo | Kod | Akcje | Pozostałe akcje | Zmiana procent |
Cena udziału |
Wartość trans |
Pozostała Wartość |
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2021-05-28 |
|
4 | MRNA |
Moderna, Inc.
Stock Option (Right to Buy) |
M - Exercise | X | -6 600 | 328 352 | -1,97 | |||
| 2021-05-28 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -6 600 | 901 | -87,99 | 174,20 | -1 149 720 | 156 954 |
| 2021-05-28 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
M - Exercise | X | 6 600 | 7 501 | 732,52 | 14,85 | 98 010 | 111 390 |
| 2021-05-27 |
|
4 | MRNA |
Moderna, Inc.
Stock Option (Right to Buy) |
M - Exercise | X | -6 600 | 334 952 | -1,93 | |||
| 2021-05-27 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -6 600 | 901 | -87,99 | 166,58 | -1 099 428 | 150 089 |
| 2021-05-27 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
M - Exercise | X | 6 600 | 7 501 | 732,52 | 14,85 | 98 010 | 111 390 |
| 2021-05-21 |
|
4 | MRNA |
Moderna, Inc.
Stock Option (Right to Buy) |
M - Exercise | X | -6 600 | 341 552 | -1,90 | |||
| 2021-05-21 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -6 600 | 901 | -87,99 | 159,92 | -1 055 472 | 144 088 |
| 2021-05-21 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
M - Exercise | X | 6 600 | 7 501 | 732,52 | 14,85 | 98 010 | 111 390 |
| 2021-05-20 |
|
4 | MRNA |
Moderna, Inc.
Stock Option (Right to Buy) |
M - Exercise | X | -6 600 | 348 152 | -1,86 | |||
| 2021-05-20 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -6 600 | 901 | -87,99 | 160,16 | -1 057 056 | 144 304 |
| 2021-05-20 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
M - Exercise | X | 6 600 | 7 501 | 732,52 | 14,85 | 98 010 | 111 390 |
| 2021-05-14 |
|
4 | MRNA |
Moderna, Inc.
Stock Option (Right to Buy) |
M - Exercise | X | -6 600 | 354 752 | -1,83 | |||
| 2021-05-14 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -6 600 | 901 | -87,99 | 152,60 | -1 007 160 | 137 493 |
| 2021-05-14 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
M - Exercise | X | 6 600 | 7 501 | 732,52 | 14,85 | 98 010 | 111 390 |
| 2021-05-13 |
|
4 | MRNA |
Moderna, Inc.
Stock Option (Right to Buy) |
M - Exercise | X | -6 170 | 361 352 | -1,68 | |||
| 2021-05-13 |
|
4 | MRNA |
Moderna, Inc.
Stock Option (Right to Buy) |
M - Exercise | X | -430 | 93 046 | -0,46 | |||
| 2021-05-13 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -6 600 | 901 | -87,99 | 151,31 | -998 646 | 136 330 |
| 2021-05-13 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
M - Exercise | X | 6 170 | 7 501 | 463,56 | 14,85 | 91 624 | 111 390 |
| 2021-05-13 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
M - Exercise | X | 430 | 1 331 | 47,72 | 20,93 | 9 000 | 27 858 |
| 2021-05-07 |
|
4 | MRNA |
Moderna, Inc.
Stock Option (Right to Buy) |
M - Exercise | X | -6 600 | 93 476 | -6,59 | |||
| 2021-05-07 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -6 600 | 901 | -87,99 | 147,82 | -975 612 | 133 186 |
| 2021-05-07 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
M - Exercise | X | 6 600 | 7 501 | 732,52 | 20,93 | 138 138 | 156 996 |
| 2021-05-06 |
|
4 | MRNA |
Moderna, Inc.
Stock Option (Right to Buy) |
M - Exercise | X | -6 600 | 100 076 | -6,19 | |||
| 2021-05-06 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -6 600 | 901 | -87,99 | 185,25 | -1 222 650 | 166 910 |
| 2021-05-06 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
M - Exercise | X | 6 600 | 7 501 | 732,52 | 20,93 | 138 138 | 156 996 |
| 2021-04-30 |
|
4 | MRNA |
Moderna, Inc.
Stock Option (Right to Buy) |
M - Exercise | X | -6 600 | 106 676 | -5,83 | |||
| 2021-04-30 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -6 600 | 901 | -87,99 | 182,49 | -1 204 434 | 164 423 |
| 2021-04-30 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
M - Exercise | X | 6 600 | 7 501 | 732,52 | 20,93 | 138 138 | 156 996 |
| 2021-04-29 |
|
4 | MRNA |
Moderna, Inc.
Stock Option (Right to Buy) |
M - Exercise | X | -6 600 | 113 276 | -5,51 | |||
| 2021-04-29 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -6 600 | 901 | -87,99 | 178,29 | -1 176 714 | 160 639 |
| 2021-04-29 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
M - Exercise | X | 6 600 | 7 501 | 732,52 | 20,93 | 138 138 | 156 996 |
| 2021-04-23 |
|
4 | MRNA |
Moderna, Inc.
Stock Option (Right to Buy) |
M - Exercise | X | -6 600 | 119 876 | -5,22 | |||
| 2021-04-23 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -6 600 | 901 | -87,99 | 168,26 | -1 110 516 | 151 602 |
| 2021-04-23 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
M - Exercise | X | 6 600 | 7 501 | 732,52 | 20,93 | 138 138 | 156 996 |
| 2021-04-22 |
|
4 | MRNA |
Moderna, Inc.
Stock Option (Right to Buy) |
M - Exercise | X | -6 600 | 126 476 | -4,96 | |||
| 2021-04-22 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -6 600 | 901 | -87,99 | 160,32 | -1 058 112 | 144 448 |
| 2021-04-22 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
M - Exercise | X | 6 600 | 7 501 | 732,52 | 20,93 | 138 138 | 156 996 |
| 2021-04-16 |
|
4 | MRNA |
Moderna, Inc.
Stock Option (Right to Buy) |
M - Exercise | X | -6 600 | 133 076 | -4,73 | |||
| 2021-04-16 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -6 600 | 901 | -87,99 | 158,76 | -1 047 816 | 143 043 |
| 2021-04-16 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
M - Exercise | X | 6 600 | 7 501 | 732,52 | 20,93 | 138 138 | 156 996 |
| 2021-04-14 |
|
4 | MRNA |
Moderna, Inc.
Stock Option (Right to Buy) |
M - Exercise | X | -6 600 | 139 676 | -4,51 | |||
| 2021-04-14 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -6 600 | 901 | -87,99 | 146,62 | -967 692 | 132 105 |
| 2021-04-14 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
M - Exercise | X | 6 600 | 7 501 | 732,52 | 20,93 | 138 138 | 156 996 |
| 2021-04-09 |
|
4 | MRNA |
Moderna, Inc.
Stock Option (Right to Buy) |
M - Exercise | X | -6 600 | 146 276 | -4,32 | |||
| 2021-04-09 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -6 600 | 901 | -87,99 | 132,85 | -876 810 | 119 698 |
| 2021-04-09 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
M - Exercise | X | 6 600 | 7 501 | 732,52 | 20,93 | 138 138 | 156 996 |
| 2021-04-08 |
|
4 | MRNA |
Moderna, Inc.
Stock Option (Right to Buy) |
M - Exercise | X | -6 600 | 152 876 | -4,14 | |||
| 2021-04-08 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -6 600 | 901 | -87,99 | 130,01 | -858 066 | 117 139 |
| 2021-04-08 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
M - Exercise | X | 6 600 | 7 501 | 732,52 | 20,93 | 138 138 | 156 996 |
| 2021-04-02 |
|
4 | MRNA |
Moderna, Inc.
Stock Option (Right to Buy) |
M - Exercise | X | -6 600 | 159 476 | -3,97 | |||
| 2021-04-02 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -6 600 | 901 | -87,99 | 132,51 | -874 566 | 119 392 |
| 2021-04-02 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
M - Exercise | X | 6 600 | 7 501 | 732,52 | 20,93 | 138 138 | 156 996 |
| 2021-04-01 |
|
4 | MRNA |
Moderna, Inc.
Stock Option (Right to Buy) |
M - Exercise | X | -6 600 | 166 076 | -3,82 | |||
| 2021-04-01 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -6 600 | 901 | -87,99 | 123,30 | -813 780 | 111 093 |
| 2021-04-01 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
M - Exercise | X | 6 600 | 7 501 | 732,52 | 20,93 | 138 138 | 156 996 |
| 2021-03-26 |
|
4 | MRNA |
Moderna, Inc.
Stock Option (Right to Buy) |
M - Exercise | X | -6 600 | 172 676 | -3,68 | |||
| 2021-03-26 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -6 600 | 901 | -87,99 | 126,88 | -837 408 | 114 319 |
| 2021-03-26 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
M - Exercise | X | 6 600 | 7 501 | 732,52 | 20,93 | 138 138 | 156 996 |
| 2021-03-25 |
|
4 | MRNA |
Moderna, Inc.
Stock Option (Right to Buy) |
M - Exercise | X | -6 600 | 179 276 | -3,55 | |||
| 2021-03-25 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -6 600 | 901 | -87,99 | 145,55 | -960 630 | 131 141 |
| 2021-03-25 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
M - Exercise | X | 6 600 | 7 501 | 732,52 | 20,93 | 138 138 | 156 996 |
| 2021-03-19 |
|
4 | MRNA |
Moderna, Inc.
Stock Option (Right to Buy) |
M - Exercise | X | -216 | 185 876 | -0,12 | |||
| 2021-03-19 |
|
4 | MRNA |
Moderna, Inc.
Stock Option (Right to Buy) |
M - Exercise | X | -6 384 | 118 155 | -5,13 | |||
| 2021-03-19 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -6 600 | 901 | -87,99 | 144,39 | -952 974 | 130 095 |
| 2021-03-19 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
M - Exercise | X | 216 | 7 501 | 2,96 | 20,93 | 4 521 | 156 996 |
| 2021-03-19 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
M - Exercise | X | 6 384 | 7 285 | 708,55 | 25,93 | 165 537 | 188 900 |
| 2021-03-18 |
|
4 | MRNA |
Moderna, Inc.
Stock Option (Right to Buy) |
M - Exercise | X | -6 600 | 124 539 | -5,03 | |||
| 2021-03-18 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -6 600 | 901 | -87,99 | 148,50 | -980 100 | 133 798 |
| 2021-03-18 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
M - Exercise | X | 6 600 | 7 501 | 732,52 | 25,93 | 171 138 | 194 501 |
| 2021-03-12 |
|
4 | MRNA |
Moderna, Inc.
Stock Option (Right to Buy) |
M - Exercise | X | -6 600 | 131 139 | -4,79 | |||
| 2021-03-12 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -6 600 | 901 | -87,99 | 133,29 | -879 714 | 120 094 |
| 2021-03-12 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
M - Exercise | X | 6 600 | 7 501 | 732,52 | 25,93 | 171 138 | 194 501 |
| 2021-03-10 |
|
4 | MRNA |
Moderna, Inc.
Stock Option (Right to Buy) |
M - Exercise | X | -6 600 | 137 739 | -4,57 | |||
| 2021-03-10 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -6 600 | 901 | -87,99 | 127,11 | -838 926 | 114 526 |
| 2021-03-10 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
M - Exercise | X | 6 600 | 7 501 | 732,52 | 25,93 | 171 138 | 194 501 |
| 2021-03-05 |
|
4 | MRNA |
Moderna, Inc.
Stock Option (Right to Buy) |
M - Exercise | X | -6 600 | 144 339 | -4,37 | |||
| 2021-03-05 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -6 600 | 901 | -87,99 | 128,58 | -848 628 | 115 851 |
| 2021-03-05 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
M - Exercise | X | 6 600 | 7 501 | 732,52 | 25,93 | 171 138 | 194 501 |
| 2021-03-04 |
|
4 | MRNA |
Moderna, Inc.
Stock Option (Right to Buy) |
M - Exercise | X | -6 600 | 150 939 | -4,19 | |||
| 2021-03-04 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -6 600 | 901 | -87,99 | 153,77 | -1 014 882 | 138 547 |
| 2021-03-04 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
M - Exercise | X | 6 600 | 7 501 | 732,52 | 25,93 | 171 138 | 194 501 |
| 2020-10-23 |
|
4 | MRNA |
Moderna, Inc.
Stock Option (Right to Buy) |
M - Exercise | X | -32 000 | 367 522 | -8,01 | |||
| 2020-10-23 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -700 | 681 | -50,69 | 71,39 | -49 973 | 48 617 |
| 2020-10-23 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -15 455 | 1 381 | -91,80 | 70,56 | -1 090 505 | 97 443 |
| 2020-10-23 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -14 148 | 16 836 | -45,66 | 69,84 | -988 096 | 1 175 826 |
| 2020-10-23 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -1 697 | 30 984 | -5,19 | 68,70 | -116 584 | 2 128 601 |
| 2020-10-23 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
M - Exercise | X | 32 000 | 32 681 | 4 698,97 | 14,85 | 475 200 | 485 313 |
| 2020-06-19 |
|
4 | MRNA |
Moderna, Inc.
Stock Option (Right to Buy) |
M - Exercise | X | -64 000 | 399 522 | -13,81 | |||
| 2020-06-19 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -64 000 | 681 | -98,95 | 63,03 | -4 033 920 | 42 923 |
| 2020-06-19 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
M - Exercise | X | 64 000 | 64 681 | 9 397,94 | 14,85 | 950 400 | 960 513 |
| 2020-06-04 |
|
4/A | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -64 000 | 0 | -100,00 | 70,00 | -4 480 000 | |
| 2020-05-22 |
|
4 | MRNA |
Moderna, Inc.
Stock Option (Right to Buy) |
M - Exercise | X | -64 000 | 463 522 | -12,13 | |||
| 2020-05-22 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -64 000 | 0 | -100,00 | 70,00 | -4 480 000 | |
| 2020-05-22 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
M - Exercise | X | 64 000 | 64 000 | 14,85 | 950 400 | 950 400 | |
| 2020-03-03 |
|
4 | MRNA |
Moderna, Inc.
Stock Option (Right to Buy) |
A - Award | 157 539 | 157 539 | |||||
| 2019-03-11 |
|
4 | MRNA |
Moderna, Inc.
Stock Option (Right to Buy) |
A - Award | 186 092 | 186 092 | |||||
| 2017-09-05 |
|
4 | AMRI |
ALBANY MOLECULAR RESEARCH INC
Option to Purchase Common Stock |
D - Sale to Issuer | -44 251 | 0 | -100,00 | 3,34 | -147 798 | ||
| 2017-09-05 |
|
4 | AMRI |
ALBANY MOLECULAR RESEARCH INC
Option to Purchase Common Stock |
D - Sale to Issuer | -29 066 | 0 | -100,00 | 5,98 | -173 815 | ||
| 2017-09-05 |
|
4 | AMRI |
ALBANY MOLECULAR RESEARCH INC
Option to Purchase Common Stock |
D - Sale to Issuer | -22 893 | 0 | -100,00 | 4,70 | -107 597 | ||
| 2017-09-05 |
|
4 | AMRI |
ALBANY MOLECULAR RESEARCH INC
Option to Purchase Common Stock |
D - Sale to Issuer | -29 167 | 0 | -100,00 | 11,32 | -330 170 | ||
| 2017-09-05 |
|
4 | AMRI |
ALBANY MOLECULAR RESEARCH INC
Option to Purchase Common Stock |
D - Sale to Issuer | -4 375 | 0 | -100,00 | 15,76 | -68 950 | ||
| 2017-09-05 |
|
4 | AMRI |
ALBANY MOLECULAR RESEARCH INC
Option to Purchase Common Stock |
D - Sale to Issuer | -4 375 | 0 | -100,00 | 15,76 | -68 950 | ||
| 2017-09-05 |
|
4 | AMRI |
ALBANY MOLECULAR RESEARCH INC
Option to Purchase Common Stock |
D - Sale to Issuer | -4 375 | 0 | -100,00 | 15,76 | -68 950 | ||
| 2017-09-05 |
|
4 | AMRI |
ALBANY MOLECULAR RESEARCH INC
Option to Purchase Common Stock |
D - Sale to Issuer | -17 500 | 0 | -100,00 | 15,76 | -275 800 | ||
| 2017-09-05 |
|
4 | AMRI |
ALBANY MOLECULAR RESEARCH INC
Option to Purchase Common Stock |
D - Sale to Issuer | -17 500 | 0 | -100,00 | 18,82 | -329 350 | ||
| 2017-09-05 |
|
4 | AMRI |
ALBANY MOLECULAR RESEARCH INC
Option to Purchase Common Stock |
D - Sale to Issuer | -4 375 | 0 | -100,00 | 18,82 | -82 338 | ||
| 2017-09-05 |
|
4 | AMRI |
ALBANY MOLECULAR RESEARCH INC
Option to Purchase Common Stock |
D - Sale to Issuer | -4 375 | 0 | -100,00 | 18,82 | -82 338 | ||
| 2017-09-05 |
|
4 | AMRI |
ALBANY MOLECULAR RESEARCH INC
Option to Purchase Common Stock |
D - Sale to Issuer | -17 500 | 0 | -100,00 | 16,50 | -288 750 | ||
| 2017-09-05 |
|
4 | AMRI |
ALBANY MOLECULAR RESEARCH INC
Option to Purchase Common Stock |
D - Sale to Issuer | -50 000 | 0 | -100,00 | 16,88 | -844 000 | ||
| 2017-09-05 |
|
4 | AMRI |
ALBANY MOLECULAR RESEARCH INC
Common Stock |
D - Sale to Issuer | -66 717 | 0 | -100,00 | 21,75 | -1 451 095 | ||
| 2017-09-05 |
|
4 | AMRI |
ALBANY MOLECULAR RESEARCH INC
Common Stock |
A - Award | 4 722 | 66 717 | 7,62 | ||||
| 2017-09-05 |
|
4 | AMRI |
ALBANY MOLECULAR RESEARCH INC
Common Stock |
G - Gift | -9 857 | 52 138 | -15,90 | ||||
| 2017-03-06 |
|
4 | AMRI |
ALBANY MOLECULAR RESEARCH INC
Common Stock |
F - Taxes | -432 | 61 995 | -0,69 | 14,52 | -6 273 | 900 167 | |
| 2017-02-10 |
|
4 | AMRI |
ALBANY MOLECULAR RESEARCH INC
Option to Purchase Common Stock |
A - Award | 44 251 | 44 251 | |||||
| 2017-02-10 |
|
4 | AMRI |
ALBANY MOLECULAR RESEARCH INC
Common Stock |
A - Award | 6 747 | 62 427 | 12,12 | ||||
| 2017-02-10 |
|
4 | AMRI |
ALBANY MOLECULAR RESEARCH INC
Common Stock |
A - Award | 8 990 | 55 680 | 19,25 | ||||
| 2017-02-07 |
|
4 | AMRI |
ALBANY MOLECULAR RESEARCH INC
Common Stock |
F - Taxes | -504 | 46 690 | -1,07 | 18,52 | -9 334 | 864 699 | |
| 2017-02-07 |
|
4 | AMRI |
ALBANY MOLECULAR RESEARCH INC
Common Stock |
F - Taxes | -674 | 47 194 | -1,41 | 18,52 | -12 482 | 874 033 | |
| 2017-02-07 |
|
4 | AMRI |
ALBANY MOLECULAR RESEARCH INC
Common Stock |
F - Taxes | -2 363 | 47 868 | -4,70 | 18,52 | -43 763 | 886 515 | |
| 2017-02-01 |
|
4 | AMRI |
ALBANY MOLECULAR RESEARCH INC
Common Stock |
F - Taxes | -553 | 50 231 | -1,09 | 18,11 | -10 015 | 909 683 | |
| 2017-02-01 |
|
4 | AMRI |
ALBANY MOLECULAR RESEARCH INC
Common Stock |
F - Taxes | -553 | 50 231 | -1,09 | 18,11 | -10 015 | 909 683 | |
| 2016-11-17 |
|
4 | AMRI |
ALBANY MOLECULAR RESEARCH INC
Common Stock |
S - Sale | -6 000 | 51 337 | -10,46 | 17,00 | -102 000 | 872 729 | |
| 2016-11-03 |
|
4 | AMRI |
ALBANY MOLECULAR RESEARCH INC
Common Stock |
F - Taxes | -409 | 57 337 | -0,71 | 15,09 | -6 172 | 865 215 | |
| 2016-03-04 |
|
4 | AMRI |
ALBANY MOLECULAR RESEARCH INC
Common Stock |
F - Taxes | -421 | 57 746 | -0,72 | 15,33 | -6 454 | 885 246 | |
| 2016-02-19 |
|
4 | AMRI |
ALBANY MOLECULAR RESEARCH INC
Common Stock |
D - Sale to Issuer | -1 459 | 58 167 | -2,45 | ||||
| 2016-02-19 |
|
4 | AMRI |
ALBANY MOLECULAR RESEARCH INC
Common Stock |
F - Taxes | -463 | 59 626 | -0,77 | 15,37 | -7 116 | 916 452 | |
| 2016-02-08 |
|
4 | AMRI |
ALBANY MOLECULAR RESEARCH INC
Option to Purchase Common Stock |
A - Award | 29 066 | 29 066 | 15,77 | 458 371 | 458 371 | ||
| 2016-02-08 |
|
4 | AMRI |
ALBANY MOLECULAR RESEARCH INC
Common Stock |
A - Award | 12 682 | 60 089 | 26,75 | 15,77 | 199 995 | 947 604 | |
| 2016-02-05 |
|
4 | AMRI |
ALBANY MOLECULAR RESEARCH INC
Common Stock |
F - Taxes | -684 | 47 407 | -1,42 | 16,16 | -11 053 | 766 097 | |
| 2016-02-01 |
|
4 | AMRI |
ALBANY MOLECULAR RESEARCH INC
Common Stock |
F - Taxes | -554 | 48 091 | -1,14 | 15,97 | -8 847 | 768 013 | |
| 2016-02-01 |
|
4 | AMRI |
ALBANY MOLECULAR RESEARCH INC
Common Stock |
F - Taxes | -554 | 48 091 | -1,14 | 15,97 | -8 847 | 768 013 | |
| 2015-11-04 |
|
4 | AMRI |
ALBANY MOLECULAR RESEARCH INC
Common Stock |
A - Award | 5 000 | 49 199 | 11,31 | 19,16 | 95 800 | 942 653 | |
| 2015-06-04 |
|
4 | AMRI |
ALBANY MOLECULAR RESEARCH INC
Common Stock |
D - Sale to Issuer | -1 459 | 44 199 | -3,20 | ||||
| 2015-06-04 |
|
4 | AMRI |
ALBANY MOLECULAR RESEARCH INC
Common Stock |
F - Taxes | -476 | 45 658 | -1,03 | ||||
| 2015-03-04 |
|
4 | AMRI |
ALBANY MOLECULAR RESEARCH INC
Option to Purchase Common Stock |
A - Award | 22 893 | 22 893 | 17,05 | 390 326 | 390 326 | ||
| 2015-03-04 |
|
4 | AMRI |
ALBANY MOLECULAR RESEARCH INC
Common Stock |
A - Award | 10 588 | 46 134 | 29,79 | 17,05 | 180 525 | 786 585 | |
| 2015-02-19 |
|
4 | AMRI |
ALBANY MOLECULAR RESEARCH INC
Common Stock |
D - Sale to Issuer | -1 458 | 35 546 | -3,94 | ||||
| 2015-02-19 |
|
4 | AMRI |
ALBANY MOLECULAR RESEARCH INC
Common Stock |
F - Taxes | -464 | 37 004 | -1,24 | ||||
| 2015-02-06 |
|
4 | AMRI |
ALBANY MOLECULAR RESEARCH INC
Common Stock |
F - Taxes | -1 582 | 37 468 | -4,05 | ||||
| 2015-02-03 |
|
4 | AMRI |
ALBANY MOLECULAR RESEARCH INC
Common Stock |
D - Sale to Issuer | -1 459 | 39 050 | -3,60 | ||||
| 2015-02-03 |
|
4 | AMRI |
ALBANY MOLECULAR RESEARCH INC
Common Stock |
F - Taxes | -554 | 40 509 | -1,35 | ||||
| 2014-10-01 |
|
4 | AMRI |
ALBANY MOLECULAR RESEARCH INC
Common Stock |
S - Sale | X | -1 000 | 41 063 | -2,38 | 21,48 | -21 480 | 882 033 |
| 2014-09-03 |
|
4 | AMRI |
ALBANY MOLECULAR RESEARCH INC
Common Stock |
S - Sale | X | -2 500 | 42 063 | -5,61 | 19,56 | -48 900 | 822 752 |
| 2014-08-13 |
|
4 | AMRI |
ALBANY MOLECULAR RESEARCH INC
Option to Purchase Common Stock |
M - Exercise | 30 000 | 50 000 | 150,00 | 4,87 | 146 100 | 243 500 | |
| 2014-08-13 |
|
4 | AMRI |
ALBANY MOLECULAR RESEARCH INC
Common Stock |
S - Sale | -30 000 | 44 563 | -40,23 | 19,05 | -571 500 | 848 925 | |
| 2014-08-13 |
|
4 | AMRI |
ALBANY MOLECULAR RESEARCH INC
Common Stock |
M - Exercise | 30 000 | 74 563 | 67,32 | 4,87 | 146 100 | 363 122 | |
| 2014-08-01 |
|
4 | AMRI |
ALBANY MOLECULAR RESEARCH INC
Common Stock |
S - Sale | X | -2 500 | 44 563 | -5,31 | 18,56 | -46 400 | 827 089 |
| 2014-07-02 |
|
4 | AMRI |
ALBANY MOLECULAR RESEARCH INC
Common Stock |
S - Sale | X | -2 500 | 47 063 | -5,04 | 20,62 | -51 550 | 970 439 |
| 2014-06-04 |
|
4 | AMRI |
ALBANY MOLECULAR RESEARCH INC
Common Stock |
F - Taxes | -476 | 49 563 | -0,95 | ||||
| 2014-06-04 |
|
4 | AMRI |
ALBANY MOLECULAR RESEARCH INC
Common Stock |
D - Sale to Issuer | -1 458 | 50 039 | -2,83 | ||||
| 2014-06-04 |
|
4 | AMRI |
ALBANY MOLECULAR RESEARCH INC
Common Stock |
S - Sale | X | -2 500 | 51 497 | -4,63 | 16,32 | -40 800 | 840 431 |
| 2014-05-01 |
|
4 | AMRI |
ALBANY MOLECULAR RESEARCH INC
Common Stock |
S - Sale | X | -2 500 | 53 997 | -4,43 | 15,73 | -39 325 | 849 373 |
| 2014-04-02 |
|
4 | AMRI |
ALBANY MOLECULAR RESEARCH INC
Common Stock |
S - Sale | X | -2 500 | 56 497 | -4,24 | 18,74 | -46 850 | 1 058 754 |
| 2014-02-19 |
|
4 | AMRI |
ALBANY MOLECULAR RESEARCH INC
Common Stock |
F - Taxes | -1 038 | 58 997 | -1,73 | ||||
| 2014-02-06 |
|
4 | AMRI |
ALBANY MOLECULAR RESEARCH INC
Option to purchase Common Stock |
A - Award | 29 167 | 29 167 | 10,43 | 304 212 | 304 212 | ||
| 2014-02-06 |
|
4 | AMRI |
ALBANY MOLECULAR RESEARCH INC
Common Stock |
A - Award | 14 584 | 60 035 | 32,09 | 10,43 | 152 111 | 626 165 | |
| 2014-02-06 |
|
4 | AMRI |
ALBANY MOLECULAR RESEARCH INC
Common Stock |
F - Taxes | -948 | 45 451 | -2,04 | ||||
| 2014-02-04 |
|
4 | AMRI |
ALBANY MOLECULAR RESEARCH INC
Common Stock |
F - Taxes | -1 106 | 46 399 | -2,33 | ||||
| 2013-06-04 |
|
4 | AMRI |
ALBANY MOLECULAR RESEARCH INC
Common Stock |
F - Taxes | -477 | 47 505 | -0,99 | ||||
| 2013-06-04 |
|
4 | AMRI |
ALBANY MOLECULAR RESEARCH INC
Common Stock |
D - Sale to Issuer | -1 458 | 47 982 | -2,95 | ||||
| 2013-02-04 |
|
4 | AMRI |
ALBANY MOLECULAR RESEARCH INC
Option to purchase Common Stock |
A - Award | 35 000 | 35 000 | 5,99 | 209 650 | 209 650 | ||
| 2013-02-04 |
|
4 | AMRI |
ALBANY MOLECULAR RESEARCH INC
Common Stock |
A - Award | 11 666 | 49 440 | 30,88 | 5,99 | 69 879 | 296 146 | |
| 2012-06-12 |
|
4 | AMRI |
ALBANY MOLECULAR RESEARCH INC
Common Stock |
D - Sale to Issuer | -1 458 | 37 774 | -3,72 | ||||
| 2012-02-21 |
|
4 | AMRI |
ALBANY MOLECULAR RESEARCH INC
Option to purchase Common Stock |
A - Award | 35 000 | 35 000 | 2,93 | 102 550 | 102 550 | ||
| 2012-02-21 |
|
4 | AMRI |
ALBANY MOLECULAR RESEARCH INC
Common Stock |
A - Award | 11 666 | 39 232 | 42,32 | 2,93 | 34 181 | 114 950 |